
lower revenu estim
ep forecast follow result miss
top-lin estim result unexpect weak rx gener
segment manag highlight challeng price headwind
price eros gener segment led signific yoy
declin oper margin announc plan spin
rx pharma segment believ time announc
less optim co plan provid addit detail septemb
report revenu vs estimate adj
ep met forecast
chc america segment perform came expect
quarter yoy impact weaker expect anim
health segment sale yoy impact late
flea tick season channel inventori
segment revenu yoy
constant currenc basi due lower analges anti-parasit
product sale time product shipment
weaker expect result post rx pharma segment
revenu came well estimate
greater expect price eros base busi product
neg impact oper margin call manag
highlight key gener product includ proair due
scopolamin patch due suppli issu would launch
valuat maintain neutral rate share
dont assign pt neutral-r stock dcf analysi suggest
share worth per share
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
prgo margin compress sinc high achiev
lower net sale guidanc adj ep
 oper cash flow guidanc lower new product sale guidanc
lower plan provid addit detail plan separ
rx pharma segment later year septemb
segment revenu lower forecast chc america yoy vs
estimate rx pharma yoy vs estimate chc revenu yoy
fell short conserv growth estim result includ adj oper margin chc
america chc rx pharma
perrigo compani plc incom statement financi project sell averag basic averag dilut analysi yoy sale dilut ep compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
